清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation

医学 依杜沙班 心房颤动 内科学 心脏病学 重症监护医学 华法林 达比加群
作者
Masaru Kuroda,Eiji Tamiya,Takahisa Nose,Akiyoshi Ogimoto,Junki Taura,Yuki Imamura,Masayuki Fukuzawa,Takuya Hayashi,Masaharu Akao,Takeshi Yamashita,Gregory Y.H. Lip,Ken Okumura
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:7 (6): 583-583 被引量:17
标识
DOI:10.1001/jamacardio.2022.0480
摘要

Importance: Long-term use of oral anticoagulants (OACs) is necessary for stroke prevention in patients with atrial fibrillation (AF). The effectiveness and safety of OACs in extremely older patients (ie, aged 80 years or older) with AF and at high risk of bleeding needs to be elucidated. Objective: To examine the effects of very low-dose edoxaban (15 mg) vs placebo across 3 age strata (80-84 years, 85-89 years, and ≥90 years) among patients with AF who were a part of the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial. Design, Setting, and Participants: This prespecified subanalysis of a phase 3, randomized, double-blind, placebo-controlled trial was conducted from August 5, 2016, to December 27, 2019. Patients with AF aged 80 years or older who were not considered candidates for standard-dose OACs were included in the study; reasons these patients could not take standard-dose OACs included low creatinine clearance (<30 mL per minute), low body weight (≤45 kg), history of bleeding from critical organs, continuous use of nonsteroidal anti-inflammatory drugs, or concomitant use of antiplatelet drugs. Eligible patients were recruited randomly from 164 hospitals in Japan and were randomly assigned 1:1 to edoxaban or placebo. Interventions: Edoxaban (15 mg once daily) or placebo. Main Outcomes and Measures: The primary efficacy end point was the composite of stroke or systemic embolism. The primary safety end point was International Society on Thrombosis and Hemostasis-defined major bleeding. Results: A total of 984 patients (mean [SD] age: age group 80-84 years, 82.2 [1.4] years; age group 85-89 years, 86.8 [1.4] years; age group ≥90 years, 92.3 [2.1] years; 565 women [57.4%]) were included in this study. In the placebo group, estimated (SE) event rates for stroke or systemic embolism increased with age and were 3.9% (1.2%) per patient-year in the group aged 80 to 84 years (n = 181), 7.3% (1.7%) per patient-year in the group aged 85 to 89 years (n = 184), and 10.1% (2.5%) per patient-year in the group aged 90 years or older (n = 127). A 15-mg dose of edoxaban consistently decreased the event rates for stroke or systemic embolism with no interaction with age (80-84 years, hazard ratio [HR], 0.41; 95% CI, 0.13-1.31; P = .13; 85-89 years, HR, 0.42; 95% CI, 0.17-0.99; P = .05; ≥90 years, HR, 0.23; 95% CI, 0.08-0.68; P = .008; interaction P = .65). Major bleeding and major or clinically relevant nonmajor bleeding events were numerically higher with edoxaban, but the differences did not reach statistical significance, and there was no interaction with age. There was no difference in the event rate for all-cause death between the edoxaban and placebo groups in all age strata. Conclusions and Relevance: Results of this subanalysis of the ELDERCARE-AF randomized clinical trial revealed that among Japanese patients aged 80 years or older with AF who were not considered candidates for standard OACs, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism consistently across all 3 age strata, including those aged 90 years or older, albeit with a higher but nonstatistically significant incidence of bleeding. Trial Registration: ClinicalTrials.gov Identifier: NCT02801669.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐的应助被tuimao采纳,获得10
11秒前
无私的碧玉完成签到,获得积分10
18秒前
丰富的德天完成签到 ,获得积分10
28秒前
科研通AI6.4的应助被TingtingGZ采纳,获得10
32秒前
简单完成签到 ,获得积分10
35秒前
外向的慕山完成签到,获得积分10
35秒前
笨笨盈完成签到,获得积分10
35秒前
44秒前
NN完成签到,获得积分10
52秒前
等待戈多发布了新的文献求助10
1分钟前
笑点低的如萱完成签到,获得积分10
1分钟前
TingtingGZ发布了新的文献求助10
1分钟前
chenchen完成签到,获得积分10
1分钟前
Wang发布了新的文献求助10
1分钟前
1分钟前
心灵美懿轩完成签到,获得积分10
1分钟前
无限鸣凤完成签到,获得积分10
1分钟前
linllll完成签到,获得积分10
1分钟前
魔幻的凝丝完成签到,获得积分10
1分钟前
我是老大的应助被TingtingGZ采纳,获得10
1分钟前
drkyy完成签到,获得积分10
1分钟前
顺利秋灵完成签到,获得积分10
2分钟前
等待戈多完成签到,获得积分10
2分钟前
漂亮的颤完成签到,获得积分10
2分钟前
2分钟前
TingtingGZ发布了新的文献求助10
2分钟前
科研通AI6.2的应助被TingtingGZ采纳,获得10
2分钟前
metoo完成签到,获得积分10
2分钟前
迷路曼荷完成签到,获得积分10
2分钟前
文艺的纸鹤完成签到,获得积分10
2分钟前
高兴战斗机完成签到,获得积分10
2分钟前
3分钟前
3分钟前
小胖子完成签到 ,获得积分10
3分钟前
ze完成签到 ,获得积分10
3分钟前
迷你的蜜粉完成签到,获得积分10
3分钟前
如意嘉熙完成签到,获得积分10
3分钟前
蜗牛好好飞完成签到,获得积分10
3分钟前
悦耳乘风完成签到,获得积分10
3分钟前
La完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767342
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697